Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial On Schedule
Jul 16th 2008Drug InformationObesity / Weight Loss / Fitness
Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX) announced that it has begun randomizing patients in ZB-202, a second Phase IIb clinical trial for Empatic(TM), one of the Company’s two late-stage obesity product candidates.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
